Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.32 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL858371 | 0.91 | KIT (0.39) | KITPIK3CAPIK3C3PRKDCLRRK2 | |
| SCHEMBL856688 | 0.90 | KIT (0.37) | KITPIK3CAPIK3C3PRKDCLRRK2 | |
| SCHEMBL856652 | 0.90 | KIT (0.37) | KITPIK3CAPIK3C3PRKDCLRRK2 | |
| SCHEMBL15462398 | 0.90 | KIT (0.37) | KITPIK3CAPIK3C3PRKDCLRRK2 | |
| SCHEMBL856439 | 0.90 | KIT (0.39) | KITPIK3CAPIK3C3PRKDCLRRK2 | |
| SCHEMBL856602 | 0.90 | PIK3C3 (0.37) | KITPIK3CAPIK3C3PRKDCLRRK2 | |
| SCHEMBL856736 | 0.90 | PIK3C3 (0.37) | KITPIK3CAPIK3C3PRKDCLRRK2 | |
| SCHEMBL855906 | 0.89 | KIT (0.37) | KITPIK3CAPIK3C3PRKDCLRRK2 | |
| SCHEMBL857172 | 0.88 | KIT (0.38) | KITPIK3CAPIK3C3PRKDC | |
| SCHEMBL857173 | 0.88 | KIT (0.38) | KITPIK3CAPIK3C3PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648066-B2 | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | KIT 224/4885PIK3CA 3/4885PIK3C3 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.